Ocular Adverse Events following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies

Abstract

We found a wide spectrum of ocular irAEs associated with immune checkpoint inhibitors. In most cases, ocular AEs did not limit ongoing cancer treatment.